RevMed’s Life-Saving Pancreatic Cancer Drug Wins Early FDA Approval

Some call it a “miracle drug,” and for people with pancreatic cancer, that’s not hyperbole.

The US Food and Drug Administration said Wednesday that it approved a trailblazing treatment for the disease from California-based biotech Revolution Medicines. Trial data showed Rasonque, the brand name for daraxonrasib, nearly doubled the rate of survival in patients with the lethal disease and could revolutionize treatment.

A Rasonque to Believe

Pancreatic cancer is considered one of the most aggressive and deadliest forms of the disease, with the five-year survival rate at just 13.7%. It’s the third leading cause of cancer deaths in the US and the National Cancer Institute estimates it will cause over 52,000 deaths this year.

Rasonque, a pill taken once daily, targets pancreatic cancers head-on by blocking mutant RAS proteins known to stimulate tumor growth. In late-stage study results, the drug helped patients whose previous treatment proved ineffective live a median 13.2 months, compared with 6.7 months for patients on chemo. In medical circles, this proved both a “eureka” and a “hallelujah” moment: When RevMed presented the results to this year’s annual meeting of the American Society of Clinical Oncology in May, they received the sort of standing ovation normally reserved for a breakout Palme d’Or contender at Cannes.

Rasonque was submitted for review in late July, and the FDA expedited approval in a little over a month by using a special “national priority voucher.” For now, it is only approved for patients with metastatic pancreatic cancer who have already received treatment or aren’t candidates for multi-agent systemic therapy rather than as an initial option. This, in part, explains why RevMed rose just 1.9% on Wednesday, which is good but hardly the stuff of game-changing scientific breakthroughs:

• RBC Capital Markets analysts wrote the FDA’s approval isn’t a “material headwind” because investors are keen for the drug to receive approval as an initial, first-line treatment for pancreatic cancer. “We expect success and an ultimate approval there,” they wrote, forecasting Rasonque could generate $1.1 billion in sales by the end of next year and an annual peak of $11.5 billion.
• Another reason is much of Rasonque’s promise has already been priced in: RevMed has soared since the trial data was released earlier this year and the stock is up more than 170% in 2026. The company’s $46 billion market capitalization now puts it ahead of biotech majors like Biogen and BioNTech. 

Room to Grow Revenue: RevMed is still testing Rasonque as a first-line therapy in previously untreated patients. Data so far has shown it outperforming other therapies. Among those taking part is former Nebraska Senator Ben Sasse, who called Rasonque a “miracle drug” for shrinking his tumors by 80% and a “nasty drug” for its side effects that include blistering rashes and diarrhea. The company is also studying the drug as a treatment for non-small cell lung cancer.